{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.6","upperLimit":"91.5","value":"87.1"},{"groupId":"OG001","lowerLimit":"76.3","upperLimit":"92.0","value":"85.4"},{"groupId":"OG002","lowerLimit":"28.4","upperLimit":"99.5","value":"80.0"},{"groupId":"OG003","lowerLimit":"51.3","upperLimit":"82.5","value":"68.4"},{"groupId":"OG004","lowerLimit":"61.1","upperLimit":"86.7","value":"75.5"},{"groupId":"OG005","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"},{"groupId":"OG006","lowerLimit":"25.0","upperLimit":"55.6","value":"39.5"},{"groupId":"OG007","lowerLimit":"10.3","upperLimit":"43.5","value":"24.1"},{"groupId":"OG008","lowerLimit":"12.9","upperLimit":"44.4","value":"26.5"},{"groupId":"OG009","lowerLimit":"0.1","upperLimit":"19.6","value":"3.8"},{"groupId":"OG010","lowerLimit":"1.1","upperLimit":"29.2","value":"9.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"49"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"43"},{"groupId":"OG007","value":"29"},{"groupId":"OG008","value":"34"},{"groupId":"OG009","value":"26"},{"groupId":"OG010","value":"22"}],"units":"Participants"}],"description":"Hematologic response: if participants met all of the following criteria of CHR: White Blood Cells ≤ institutional upper limit of normal, no peripheral blood blasts or promyelocytes, myelocytes+metamyelocytes \\<5% in blood, absolute neutrophil count ≥ 1.0×10\\^9/L , platelets \\<450×10\\^9/L, platelets ≥100×10\\^9/L, \\<20% basophils in blood and no extramedually involvement (including hepato- or splenomegaly), ≤5% BM blasts (required for ADV only and applicable to CP if BM aspirate was performed).","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"OG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"OG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"OG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"OG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP IM R/I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG006","title":"Bosutinib 500 mg, AP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG007","title":"Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP IM R/I CML ; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG008","title":"Bosutinib 500 mg, BP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG009","title":"Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"OG010","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"paramType":"NUMBER","populationDescription":"Hematologic evaluable population included all enrolled participants who received at least one dose of study medication and had an adequate baseline hematologic assessment.","reportingStatus":"POSTED","timeFrame":"Day 1 and 7 of Week 1, Day 7 of Week 2, 3, 4, 8, 12, thereafter assessed every 12 weeks up to 2 years then every 24 weeks thereafter up to Year 4 (CP3L and ADV) or Year 5 (CP2L)","title":"Percentage of Participants With Confirmed Complete Hematologic Response (CHR) - Part 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}